Introduction
Childhood intractable epilepsy (IE) accounts for 20-30% of all cases of epilepsy [1] . IE is not completely controlled by treatment with two or more classes of antiepileptic drugs, therefore is also known as drug-resistant childhood epilepsy [1] . Immune responses are implicated in seizure induction and the development of epilepsy [2, 3] , however the immunological pathogenesis of IE is unclear. In general, prolonged or recurrent seizures and brain injuries could lead to up-regulation of proinflammatory cytokines, and thus further increase susceptibility to seizures and promote neuronal excitability [2, 3] . The mechanisms responsible for increased levels of proinflammatory cytokines and aberrant immune responses in IE remain to be elucidated. In addition to Th1 and Th2T cells, pro-inflammatory T helper type 17 (Th17) cells and anti-inflammatory CD4 + CD25 +
Foxp3
+ regulatory T cells (Tregs) have been characterized [4, 5] . Treg cells expressing the transcription factor P3 (Foxp3), GITR, CTLA-4 have an antiinflammatory role and maintain tolerance to self components, while Th17 cells expressing retinoic acid-related orphan receptor gt (RORgt) play critical reactions by producing IL-17 [4, 5] . Th17
and Tregs are involved in maintaining dynamic balance in various types of inflammation and autoimmune diseases [6, 7] . Previous studies have indicated that circulating levels of CD4 + T cells and natural killer cells are depressed in patients with epilepsy [8] , however, to our knowledge, little data is available on the levels of Th17 and Treg cells in refractory epilepsy. The ketogenic diet (KD) is a high-fat, adequate-protein and lowcarbohydrate diet which has been proven to be an effective and safe treatment for refractory epilepsy [9] [10] [11] . Adherence to KD is associated with improvement in seizure control, which persists for long time even after the diet has been discontinued [9] [10] [11] , however the mechanisms responsible for these effects are unclear. It has been reported that KD may reduce convulsions by inhibiting Seizure 38 (2016) [17] [18] [19] [20] [21] [22] Purpose: The ketogenic diet (KD) is an effective treatment for intractable epilepsy (IE), however the therapeutic mechanism is still unclear. This study was designed to investigate T helper type 17/ regulatory T cell (Th17/Treg) levels in children with IE and age-matched healthy controls following KD. Method: Circulating levels of Th17/Treg cells were analyzed by flow cytometry. Plasma concentration of interleukin (IL)-17 was measured by cytometric bead array assay. Real-time PCR was performed to measure mRNA levels of mTOR, HIF1a and Th17/Treg associated factors in purified CD4 + CD25 + T and
Results: By one-way ANOVA, the proportion of circulating Th17 cells and expression of IL-17A and RORgt were significantly higher (P < .05), while the proportion of circulating Tregs and expression of Foxp3, GITR, CTLA-4 were significantly lower (P < .05) in IE patients than healthy subjects. However, these alternations were reversed following KD (P < .05). In CD4 + CD25 + T and CD4 + CD25 À T cells mTOR and HIF1a expression were significantly higher in IE patients (P < .05), however KD reduced mTOR and HIF1a expression (P < .05). The plasma IL-17A concentrations were higher in IE patients than controls (P < .05). KD partially reduced IL-17A levels (P < .05).
Conclusion:
Our results suggest that Th17/Treg imbalance is characteristic of childhood IE, and may contribute to IE pathogenesis. KD treatment is able to correct this imbalance, probably via inhabiting the mTOR/HIF-1a signaling pathway. ß 2016 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
the mammalian target of rapamycin (mTOR) signaling pathway [12] . Recent research into Th17 development has revealed that mTOR-induced hypoxiainduced factor (HIF)-1a determined the differentiation of naive CD4 + T cells into Th17 cells or Tregs [13, 14] , however it is unknown whether KD would affect the balance of Th17/Treg cells in intractable childhood epilepsy. In this study, we investigated the levels of Th17 and Treg cells in IE patients and healthy subjects, and evaluated mediators of the mTOR/HIF-1a signaling pathway before and after KD to further explore the effect of KD on the disturbed immune response in intractable childhood epilepsy.
Materials and methods

Subjects
Twenty-eight children (16 males and 12 females; age range: 7 months to 11 years; median age: 19 months) diagnosed with IE and 14 age-matched healthy children (8 males and 6 females; median age: 16 months; age range: 6 months to 10 years) (Control) were enrolled in this study. Participants were inpatients of Shenzhen Children' Hospital between July 2013 and December 2013, without metabolic disorders, infection, and had not taken immune modulators or experienced any severe systemic illnesses within 3 months prior to study initiation. All IE patients had received three or more classes of antiepileptic drugs, however frequent seizures continued (>4 times/week). The participants included 14 cases of West syndrome, of which two had a family history of epilepsy, two had tuberous sclerosis, and two had a history of neonatal hypoxic-ischemic encephalopathy; 8 cases of partial seizures, of which one had a family history of epilepsy, and one had a family history of febrile convulsions; 3 cases of structural abnormalities of the brain; 2 cases of a history of brain surgery; one case of Dravet syndrome, with a family history of febrile convulsions. The psychomotor development of 24 cases lagged behind that of age-matched healthy children, while the remaining 4 patients had normal psychomotor development. All patients underwent imaging and abnormalities were observed in 5 cases, of which two had tuberous sclerosis and three had cerebral hypoplasia ( Table 1 ). The parents of the patients ensured adherence to the KD.
All IE patients were treated with the John Hopkins Hospital protocol with an initial fasting stage of about 24-48 h, and a diet lipid-to-non lipid ratio of 4:1. Every patient was provided an average energy intake of 60-80 kcal/kg per day, with 1-1.5 g/kg of protein supplemented with potassium citrate, multi-vitamins and essential minerals. Healthy subjects did not receive the KD. Following the initiation of the study, the antiepileptic drugs and doses used were not changed from those administered previously. Blood samples were collected from the intractable epilepsy patients 9-10 days before and after KD treatment. During KD treatment, blood glucose, blood ketone and urine ketone were maintained steady for at least 7 days. The frequency of seizure was recorded. Seven days after KD treatment, 60% of IE patients showed that the seizure frequency was decreased, and the efficacy rate was 50% (seizure free, 0 case; seizure reduction !50%, 14 cases; seizure reduction <50%, 3 cases; no change, 11 cases) ( Table 2) .
The study was conducted in accordance with the Declaration of Helsinki and with the approval of the Ethics Committee of Shenzhen Children' Hospital. Written informed consent was obtained from the legal guardians of all participants.
Blood samples
Venous blood (5 mL) was taken from patients with KD and healthy subjects using EDTA-Na 2 as the anti-coagulant. Peripheral blood mononuclear cells (PBMCs) were prepared by Ficoll density gradient for flow cytometric analysis. Plasma was obtained after centrifugation and stored at À80 8C for cytometric bead array (CBA). CD4 + CD25 + T and CD4 + CD25 À T cells were isolated immediately from children's peripheral blood using Dynal microbeads (11363D, Dynal, Invitrogen, USA) according to the manufacturer's instructions. Isolated cell purity of >97% was confirmed flow cytometry (FCM), and viability >95% by 0.05% was confirmed by trypan blue staining.
Total RNA extraction and cDNA synthesis
Total RNA was isolated from CD4 + CD25 + T cells or CD4 + CD25 À T cells using Versagene gene RNA kit (Gentra 0050C, USA), according to the manufacturer's instructions (Gentra 0050D, USA). Isolated total RNA integrity was verified by an average optical density OD 260 /OD 280 absorption ratio of 1:98. Using RevertAidTM H Minus Moloney murine leukemia virus (MMLV) reverse transcriptase (K1632#; Fermentas, Vilnius, Lithuania), cDNA was synthesized with oligo-dT prime. Negative control samples (no firststrand synthesis) were prepared by performing the reverse transcription reaction in the absence of reverse transcriptase.
LightCycler real-time PCR
Cellular cDNA levels of IL-17A, RORgt, Foxp3, GITR, CTLA4, mTOR, HIF1a in CD4 + CD25 + T and CD4 + CD25 À T cells were quantitated by real-time PCR, using Quantitect TM SYBR green PCR Kit (Takara, DRR820S, Dalian, China) and a LightCycler 1 2.0 Instrument (Roche Molecular Biochemicals, Switzerland). The primers used for real-time PCR are listed in Table 3 . The second derivate maximum method was performed for CP determination using LightCycler Software V3.5.30 (Roche Molecular Biochemicals). After normalization with Relative Quantification Software V1.0 (Roche Molecular Biochemicals), the results were presented as ratios of the target gene mRNA to GAPDH mRNA. The efficacy rate = (Number of completely seizure free + Seizure reduction !50%) À Total number of cases Â 100. The seizure reduction rate = (Number of completely seizure free + Seizure reduction !50% + Seizure reduction <50%) À Total number of cases Â 100.
Flow cytometry analysis of Th17 cells and Tregs
To 
CBA detection of plasma IL-17A
The plasma level of IL-17A was measured using a cytometric bead array (CBA) kit (eBioscience, USA), following the manufacturer's instructions. All samples were measured in duplicate.
Statistical analysis
Statistical analysis was carried out using SPSS for Windows version 13.0 (SPSS, Chicago, IL, USA). The results are presented as mean AE standard deviation. Differences between the values were determined using one-way ANOVA. P < .05 was considered statistically significant.
Results
Circulating Th17 and Treg frequencies
To investigate the circulating levels of Th17 and Treg cells in children with IE the frequencies of Th17 and Treg cells in peripheral blood was measured by flow cytometry (Fig. 1) . The proportion of Th17 cells was markedly higher in the 28 IE patients than the 14 healthy subjects (2.61 AE 0.46% vs. 1.32 AE 0.33%, P < .05), and the mean frequency of Th17 cells decreased after KD treatment (1.51 AE 0.40%, P < .05) (Fig. 1A, C) .
In contrast, the proportion of peripheral Treg cells in IE patients was significantly lower than healthy subjects (1.74 AE 0.54% vs. 3.96 AE 0.29%, P < .05), and increased gradually after KD treatment (3.12 AE 0.94%, P < .05) (Fig. 1B, C) . (Fig. 2) . In contrast, the expression levels of Foxp3, GITR, CTLA-4 mRNA were significantly lower in IE patients than healthy subjects (Foxp3: 12.50 AE 5. , P < .05) (Fig. 2). 
Expression of Th17 transcription factor and Tregs associated factors
The expression of mTOR and HIF-1a
HIF1a and mTOR regulate Th17 and Treg differentiation, therefore we measured mRNA levels of these genes by real-time PCR. As shown in Fig. 3 , compared with healthy subjects.
The levels of HIF-1a and mTOR expression were significantly in IE patients than healthy subjects in CD4 , P < .05). Plasma concentrations of IL-17A were significantly higher in IE patients than healthy subjects (IL-17A 26.89 AE 6.58 vs. 13.92 AE 2.98, P < .05), but decreased dramatically following KD (IL-17A 19.13 AE 5.94, P < .05) (Fig. 4) .
Discussion
The balance between pro-inflammatory Th17 cells and antiinflammatory Tregs can be influenced by drivers of Treg development and function such as Foxp3 [15] [16] [17] . Several studies in humans and mice have reported that Th17/Treg cells play an populations were compared with IE using one-way ANOVA. *P < .05.
important role in the pathogenesis of a diverse group of immunemediated diseases including multiple sclerosis, experimental autoimmune encephalomyelitis, and rheumatoid arthritis [4] [5] [6] [7] . In this study we investigated the balance between The serine/threonine kinase mTOR directly influences T cell differentiation and proliferation by integrating environmental cues including nutrients, energy stores and growth factors [18] . The capacity of mTOR to integrate diverse signals from the immune microenvironment and coordinate immune cell metabolism and function is increasingly recognized [13, 19] . More specifically, inhibition of mTOR signaling, either through gene deficiency or rapamycin treatment in vitro and in vivo, promotes differentiation to Tregs or Th17 cells, respectively [13, [19] [20] [21] [22] [23] . In this study, we found that mTOR expression was significantly elevated in IE patients, but significantly down-regulated following KD. Therefore, we speculate that over-expression of mTOR might contribute to the Th17/Treg imbalance in IE.
The key metabolic sensor HIF-1 is a heterodimeric protein consisting of the constitutively expressed b subunit and an inducible a subunit. Dang et al. [24] demonstrated that HIF-1 regulates the balance between Treg and Th17 differentiation. HIF-1a enhances Th17 development through direct transcriptional activation of RORgt, and concurrently, attenuates Treg development, by binding Foxp3 and targeting it for proteasomal degradation [14, 24, 25] . Moreover, mTOR signaling is essential to induce HIF-1a expression in Th17 cells, suggesting that HIF-1a is an integral downstream mediation of mTOR that mediates Th17 and Treg cell differentiation [13, 14] . In our study, we found elevated expression of HIF-1a in IE patients, which was significantly ameliorated following KD treatment. Therefore, we speculate that over-expression of HIF-1a, resulting from abnormal expression of mTOR, may also contribute to the Th17/Treg imbalance in IE. The KD is an effective treatment for IE that appears to confer not only traditional anticonvulsant and anti-inflammatory effects, but also disease-modifying and antiepileptogenic properties in humans and animal models [9] [10] [11] 26] . A better understanding of the therapeutic mechanisms of KD may help elucidate the pathalogical immune responses involved in epileptogenesis and to identify potential therapeutic targets for more effective antiepileptic agents. In our study, over-expression of mTOR and HIF-1a were reversed while aberrant Tregs and Th17 cells were restored after KD. It is possible that KD may regulate the Th17/ Treg balance via inhibiting the mTOR/HIF-1a pathway in IE. Although further study will be required to better understand the mechanisms, our novel finding may inform the search for new promising targets for KD.
In summary, our study revealed that an existing imbalance of Th17/Treg in childhood IE. KD, which is clinically proven therapy for IE, was found to increase the differentiation of Treg cells and lead to a concomitant decrease in Th17 cell generation in IE, probably via inhibition of mTOR/HIF-1a signaling pathway. Our novel finding may explain the mechanisms for the anticonvulsant and anti-inflammatory effects of KD. Our study is limited by the small sample size and short times, so the therapeutic effect of KD cannot be determined by this kind of study. Further studies are warranted to explore the mTOR/HIF-1a signaling pathway affecting Th17/Treg balance in IE.
